Cyltezo, made by Boehringer Ingelheim, is the second interchangeable biosimilar drug approved by the FDA, following the approval of Mylan’s Semglee in July. It is the first interchangeable monoclonal antibody approved.
An interchangeable biosimilar drug is one that can be subsistuted for its reference product — in Cyltezo’s case, Humira — without the prescriber having to change the prescription. The substitution can occur at the pharmacy, similar to how generic drugs are substituted for brand-name drugs, subject to state pharmacy laws.
Cyltezo can treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis and more. It is administered subcutaneously by a physician.
Read the FDA’s full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.